Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour mutational burden and survival with molecularly matched therapy.
de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I. de Bortoli T, et al. Among authors: frohling s. Eur J Cancer. 2023 Sep;190:112925. doi: 10.1016/j.ejca.2023.05.013. Eur J Cancer. 2023. PMID: 37544709
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Budczies J, et al. Among authors: frohling s. Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30. Genes Chromosomes Cancer. 2016. PMID: 27106868
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Dieter SM, et al. Among authors: frohling s. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. Ann Oncol. 2017. PMID: 27687311 Free article.
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.
Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Gröschel S, et al. Among authors: frohling s. Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180. doi: 10.1101/mcs.a001180. Cold Spring Harb Mol Case Stud. 2016. PMID: 27900363 Free PMC article.
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.
Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A. Budczies J, et al. Among authors: frohling s. Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017. Oncoimmunology. 2017. PMID: 28405504 Free PMC article.
Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S. Horak P, et al. Among authors: frohling s. Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28597939
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D. Ugurel S, et al. Among authors: frohling s. Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735071 No abstract available.
[Personalized oncology].
Heining C, Horak P, Gröschel S, Glimm H, Fröhling S. Heining C, et al. Among authors: frohling s. Radiologe. 2017 Oct;57(10):804-811. doi: 10.1007/s00117-017-0297-9. Radiologe. 2017. PMID: 28875369 Review. German.
311 results